These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 29865055)

  • 1. Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade.
    Gulisano W; Maugeri D; Baltrons MA; Fà M; Amato A; Palmeri A; D'Adamio L; Grassi C; Devanand DP; Honig LS; Puzzo D; Arancio O
    J Alzheimers Dis; 2018; 64(s1):S611-S631. PubMed ID: 29865055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.
    Shin WS; Di J; Cao Q; Li B; Seidler PM; Murray KA; Bitan G; Jiang L
    Alzheimers Res Ther; 2019 Oct; 11(1):86. PubMed ID: 31627745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.
    Liao D; Miller EC; Teravskis PJ
    Eur J Neurosci; 2014 Apr; 39(7):1202-13. PubMed ID: 24712999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACH2.0/E, the Consolidated Theory of Conventional and Unconventional Alzheimer's Disease: Origins, Progression, and Therapeutic Strategies.
    Volloch V; Rits-Volloch S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Amyloid Cascade Hypothesis 2.0 for Alzheimer's Disease and Aging-Associated Cognitive Decline: From Molecular Basis to Effective Therapy.
    Volloch V; Rits-Volloch S
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
    Dunys J; Valverde A; Checler F
    J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
    Manczak M; Reddy PH
    Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes.
    Fein JA; Sokolow S; Miller CA; Vinters HV; Yang F; Cole GM; Gylys KH
    Am J Pathol; 2008 Jun; 172(6):1683-92. PubMed ID: 18467692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach.
    Haut F; Argyrousi EK; Arancio O
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
    Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
    Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer disease therapy--moving from amyloid-β to tau.
    Giacobini E; Gold G
    Nat Rev Neurol; 2013 Dec; 9(12):677-86. PubMed ID: 24217510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy between amyloid-β and tau in Alzheimer's disease.
    Busche MA; Hyman BT
    Nat Neurosci; 2020 Oct; 23(10):1183-1193. PubMed ID: 32778792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
    Reddy PH; Oliver DM
    Cells; 2019 May; 8(5):. PubMed ID: 31121890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel AβPP M722K Mutation Affects Amyloid-β Secretion and Tau Phosphorylation and May Cause Early-Onset Familial Alzheimer's Disease in Chinese Individuals.
    Wang Q; Jia J; Qin W; Wu L; Li D; Wang Q; Li H
    J Alzheimers Dis; 2015; 47(1):157-65. PubMed ID: 26402764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.